Current Therapeutic Research-clinical and Experimental最新文献

{"title":"Renal Dysfunction in a Patient With Crohn's Disease During Ustekinumab Treatment: A Case Report and Review of the Literature","authors":"Yuge Wei Ms ,&nbsp;Gechong Ruan MD ,&nbsp;Yan Qin MD ,&nbsp;Xiaoyin Bai MD ,&nbsp;Hong Yang MD","doi":"10.1016/j.curtheres.2024.100753","DOIUrl":"10.1016/j.curtheres.2024.100753","url":null,"abstract":"<div><p>Ustekinumab is a first-line drug for Crohn's disease. However, little is known about its potential adverse effects on renal function. We present the case of a 42-year-old man with Crohn's disease who developed chronic renal dysfunction during ustekinumab treatment, which resolved after discontinuing ustekinumab. The findings underscore the importance of close monitoring of renal function in patients receiving ustekinumab, particularly those with preexisting kidney disease or risk factors for renal dysfunction.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"101 ","pages":"Article 100753"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000237/pdfft?md5=973e2706e144156c62b3cd11237e0105&pid=1-s2.0-S0011393X24000237-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141689129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IVsight as an Infusion Monitor for Patients Receiving Intravenous Therapy: An Exploratory, Unblinded, Single-Center Trial","authors":"Carlos Mejia-Chew MD ,&nbsp;Brett Heuring PharmD ,&nbsp;Jeffrey Salmons RN ,&nbsp;Lori Weilmuenster PharmD ,&nbsp;Joe Beggs BEng ,&nbsp;Glen Kleinschmidt BEng ,&nbsp;Jake Eshelman BEng ,&nbsp;Sai Dodda PharmD","doi":"10.1016/j.curtheres.2024.100747","DOIUrl":"10.1016/j.curtheres.2024.100747","url":null,"abstract":"<div><h3>Background</h3><p>Intravenous (IV) infusion therapy is commonly used in health care settings. However, IV therapy at home can be challenging because it relies on the patient's ability to manage multiple medications correctly, which may lead to decreased treatment adherence.</p></div><div><h3>Objective</h3><p>We aimed to assess the usability and accuracy of the IVsight monitor in capturing IV infusion data compared to manual recording.</p></div><div><h3>Methods</h3><p>A prospective, single-center, usability study involving patients receiving IV infusion therapy at one of the BJC's Home Infusion suites was conducted to evaluate the accuracy, performance, and acceptability of the device IVsight as a monitor for IV infusions.</p></div><div><h3>Results</h3><p>Of the 15 participants, the median (IQR) age was 46 years (36–55), 8 (53%) were female, and 13 (87%) were non-Hispanic white. Each participant received a median (IQR) of 4 (4–5) infusions during the study, and 68 infusions were observed overall. The intraclass correlation coefficient between the IVsight measurement and manual recording of infusion duration in seconds was excellent (ICC 0.97, 95% confidence interval 0.96–0.98). The Bland–Altman plot visually showed an acceptable limit of agreement for the 2 measurements, and the linear regression analysis revealed no significant proportional bias between the 2 methods for measuring the IV infusion time. None of the participants thought that IVsight was difficult to hold, use, clean, or store. Only one participant was concerned that the device could interfere with the IV infusion, and all participants felt comfortable with the device transmitting data to their health care providers.</p></div><div><h3>Conclusions</h3><p>The IVsight infusion monitoring device showed near-perfect agreement on the recorded IV infusion duration compared with manual recording, and good acceptability among the study participants.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100747"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000171/pdfft?md5=80fd87cb1f8920d6b08acb8349f56587&pid=1-s2.0-S0011393X24000171-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140778667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficiency of Dipeptidyl Peptidase IV Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis","authors":"Adili Tuersun M.A. ,&nbsp;Munire Mohetaer M.A. ,&nbsp;Guanxin Hou B.A. ,&nbsp;Gang Cheng Ph.D","doi":"10.1016/j.curtheres.2024.100763","DOIUrl":"10.1016/j.curtheres.2024.100763","url":null,"abstract":"<div><h3>Background</h3><div>To investigate the safety and efficiency of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetic kidney disease.</div></div><div><h3>Methods</h3><div>We conducted a comprehensive literature search across multiple databases, including Embase, PubMed, CNKI, and the Cochrane Central Register of Controlled Trials, from inception to January 2024. The search focused on randomized controlled trials (RCTs) that directly compared DPP-4 inhibitors with placebos or other glucose-lowering therapies. A meta-analysis was performed to pool data and quantify the therapeutic effects and safety profile of DPP-4 inhibitors in DKD.</div></div><div><h3>Results</h3><div>Twenty-three RCTs with 16,378 participants were included. DPP-4 inhibitors significantly reduced urinary albumin-to-creatinine ratio (UACR) and HbA1c levels compared to controls (UACR: SMD -0.23, 95% CI: -0.41, -0.06; <em>p</em> = 0.01; HbA1c: SMD -0.32, 95% CI: -0.51, -0.14; <em>p</em> = 0.0006). A higher proportion of patients in the DPP-4 inhibitor group achieved at least a 30% reduction in UACR (OR = 1.73, 95% CI: 1.10, 2.73; <em>p</em> = 0.02). However, estimated glomerular filtration rate (eGFR) and serum creatinine (SCr) changes were similar between groups (eGFR: <em>p</em> = 1.00; SCr: <em>p</em> = 0.67). No significant differences were found in all-cause mortality (OR = 0.94, 95% CI: 0.83, 1.06; <em>p</em> = 0.31) or hypoglycemia risk (OR = 1.10, 95% CI: 0.80, 1.52; <em>p</em> = 0.54) between the DPP-4 inhibitor and control groups.</div></div><div><h3>Conclusions</h3><div>DPP-4 inhibitors exhibit renoprotective properties, indicated by significant reductions in UACR and HbA1c levels. They do not appear to increase the risk of hypoglycemia, presenting a favorable safety profile when compared to placebo or alternative antidiabetic agents.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"101 ","pages":"Article 100763"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison Between Moxifloxacin and Chloramphenicol for the Treatment of Bacterial Eye Infections","authors":"Valentina Gentili PhD ,&nbsp;Giovanni Strazzabosco MS ,&nbsp;Rossella Spena MD ,&nbsp;Sabrina Rizzo MS ,&nbsp;Silvia Beltrami MS ,&nbsp;Giovanna Schiuma MS ,&nbsp;Andrea Alogna MS ,&nbsp;Roberta Rizzo PhD","doi":"10.1016/j.curtheres.2024.100740","DOIUrl":"https://doi.org/10.1016/j.curtheres.2024.100740","url":null,"abstract":"<div><h3>Background</h3><p>Moxifloxacin is a bactericidal methoxyquinolone used for the treatment of conjunctivitis and prophylactic therapy in cataract and refractive surgeries. Chloramphenicol is a bacteriostatic organochlorine introduced into clinical practice in 1948 and used mainly in topical preparations because of its known toxicity.</p></div><div><h3>Objectives</h3><p>The study aimed to evaluate the in vitro antibacterial effect and the ocular cytotoxicity of these broad-spectrum antibiotics.</p></div><div><h3>Methods</h3><p>Antimicrobic activity was tested on 4 bacteria strains (<em>Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus,</em> and <em>Staphylococcus epidermidis</em>), and determined through calculation of MIC and half inhibitory concentration for each microorganism. Antibacterial activity was determined by microdilution method after 24 hours’ incubation with 2-fold serial dilutions (2.5 mg/mL to 4.883 µg/mL) of moxifloxacin and chloramphenicol. Disk diffusion test were performed according to European Committee on Antimicrobial Susceptibility Testing methodology. Biofilm formation inhibition and biofilm eradication concentration assay were conducted for <em>P aeruginosa</em> and <em>S epidermidis</em> using the microdilution method. Cytotoxicity of antibiotics was evaluated by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) colorimetric assay on human corneal cell.</p></div><div><h3>Results</h3><p>Cytotoxicity of antibiotics was evaluated on human epithelial corneal cells after 4 hours treatment by viability assay. Results showed that corneal cell viability was significantly higher after moxifloxacin treatment compared with chloramphenicol (<em>P</em> &lt; 0.01). Moxifloxacin is characterized by a significantly lower MIC and half inhibitory concentration values and a larger inhibition zone for all the strain tested, with high performance in controlling gram-negative growth, compared with chloramphenicol. Moreover, moxifloxacin showed higher activity compared with chloramphenicol in the inhibition of biofilm formation and in the disruption of biofilm, especially against <em>S epidermidis</em> biofilm.</p></div><div><h3>Conclusions</h3><p>The lower corneal cell toxicity and the broader spectrum of antibacterial activity observed with moxifloxacin suggests its use in ophthalmic solution for the treatment of bacterial eye infections.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100740"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000109/pdfft?md5=8b6bfd7065291c3dad22bc467f0a7fec&pid=1-s2.0-S0011393X24000109-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140113003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potentially Inappropriate Medications Use and Associated Factors Among Older Patients on Follow-Up at the Chronic Care Clinic of Hiwot Fana Comprehensive Specialized Hospital in Eastern Ethiopia","authors":"Shambel Nigussie M.Sc. ,&nbsp;Fekade Demeke MPH","doi":"10.1016/j.curtheres.2023.100730","DOIUrl":"10.1016/j.curtheres.2023.100730","url":null,"abstract":"<div><h3>Background</h3><p>Potentially inappropriate medications (PIMs) use often cause to poor health outcomes in older patients. There is a dearth of information on PIMS use in this population of patients seeking treatment at Hiwot Fana Comprehensive Specialized Hospital.</p></div><div><h3>Objective</h3><p>To assess PIMs use and associated factors among older patients receiving follow-up treatment at the chronic care clinic of Hiwot Fana Comprehensive Specialized Hospital in eastern Ethiopia.</p></div><div><h3>Methods</h3><p>A retrospective cross-sectional study using medical records of 419 older patients was conducted. older patients, aged 65 years or older, treated in the ambulatory care clinic were included. Simple random sampling technique was used. PIMs use was identified by using the 2023 American Geriatrics Society Beers Criteria (AGS Beers Criteria) and Screening Tool of Older People's Potentially Inappropriate Prescriptions Criteria and Screening Tool to Alert Doctors to Right Treatment (STOPP/START) version 2 criteria. The multivariable logistic regression analysis was employed to identify factors associated with PIMs use. The strength of statistical association was measured by adjusted odds ratio (aOR) and 95% CI. <em>P</em> values &lt; 0.05 were considered statistically significant.</p></div><div><h3>Results</h3><p>A total of 419 patients’ medical records were reviewed. Of these, 411 patients’ medical records fulfilled the inclusion criteria and were considered for final analysis. About 56.9% (n= 234) of the study population was women. The prevalence of PIMs use was 28.5% and 18.5%, according to 2023 AGS Beers Criteria and STOPP/START version 2 criteria, respectively. In accordance with 2023 AGS Beers Criteria, male sex (aOR = 1.78; 95% CI, 1.10–2.87), diabetes mellitus (aOR = 0.35; 95% CI, 0.19–0.62), and chronic kidney disease (aOR = 6.68; 95% CI, 2.55–9.32) were found to be the determining factors for PIMs use. According to STOPP/START version 2 criteria, deep vein thrombosis, diabetes mellitus, hypertension, and advanced age were the primary factors influencing PIMs use.</p></div><div><h3>Conclusions</h3><p>Compared with other study findings from across the world, the prevalence of PIMs use was low. Based on 2023 AGS Beers Criteria, male sex, diabetes mellitus, and chronic kidney disease were found to be the determinant factors for PIMs use. Deep vein thrombosis, diabetes mellitus, hypertension, and advanced age were significant factor of PIMs use according STOPP/START version 2 criteria.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100730"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X23000395/pdfft?md5=0cb41b1e39973ce34caf71b625e9dade&pid=1-s2.0-S0011393X23000395-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139018478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Coagulation and Prognosis of Gastric Cancer: A Systematic Review and Meta-Analysis","authors":"Lihui Zhu ,&nbsp;Shuo Liu ,&nbsp;Da Wang ,&nbsp;Miao Yu ,&nbsp;Hui Cai","doi":"10.1016/j.curtheres.2024.100741","DOIUrl":"10.1016/j.curtheres.2024.100741","url":null,"abstract":"<div><h3>Background</h3><div>The hypercoagulable state of cancer patients is associated with their high mortality rate. Coagulation indicators may have an important role in the prognosis of gastric cancer patients and deserve to be explored in various aspects.</div></div><div><h3>Objective</h3><div>We conducted a meta-analysis to explore the correlation between coagulation and prognosis of gastric cancer.</div></div><div><h3>Methods</h3><div>A comprehensive systematic search was conducted in PubMed, Embase, Web of Science databases, and the Cochrane Library up to February 16, 2024. Literature screening and data extraction were performed by two independent reviewers. The processed data we pooled using either a random-effects model or a fixed-effects model and finally described overall survival with a risk ratio (hazard ratio [HR]) and predicted the likelihood of different clinicopathological events with a dominance ratio (OR).</div></div><div><h3>Results</h3><div>A total of 64 studies were screened for inclusion in the data analysis. Performing a meta-analysis of three indicators we derived that the risk of <span>d</span>-dimer (D-D), fibrinogen (FIB), and platelets (PLTs) were: HR = 1.85 (95% confidence interval [CI]: 1.59–2.15, <em>N</em> = 15), HR = 1.77 (95% CI: 1.57–1.99, <em>N</em> = 28), HR = 1.16 (95% CI: 1.12–1.21, <em>N</em> = 29). In addition to this, all three were associated with advanced clinicopathological stage (D-D: OR = 2.25, FIB: OR = 2.07, PLT: OR = 1.84), T stage (D-D: OR = 2.30, FIB: OR = 2.38, PLT: OR = 2.22) and lymph node metastasis (D-D: OR = 1.79, FIB: OR = 1.70, PLT: OR = 1.51).</div></div><div><h3>Conclusion</h3><div>Overall, the findings suggest that the three indicators, D-D, FIB, and PLT count, have significant predictive value for the prognosis of gastric cancer. They were associated with an advanced clinicopathological stage and a high risk of lymph node metastasis.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"101 ","pages":"Article 100741"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140281690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Adding Sitagliptin to Ongoing Metformin on Metabolic Profile, Triglyceride-Glucose Index, Vitamin D3, and Liver Tests in Patients Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial","authors":"Habib Yaribeygi PhD ,&nbsp;Majid Ramezani MD ,&nbsp;Niki Katsiki PhD, MD ,&nbsp;Majid Mirmohammadkhani PhD ,&nbsp;Narges Sadat Tabaei Msc","doi":"10.1016/j.curtheres.2024.100764","DOIUrl":"10.1016/j.curtheres.2024.100764","url":null,"abstract":"<div><h3>Background</h3><div>Dipeptidyl peptidase-4 inhibitors provide potent antidiabetic effects in patients with type 2 diabetes mellitus (T2DM), but their role in the presence of nonalcoholic fatty liver disease (NAFLD) is not well-known.</div></div><div><h3>Objective</h3><div>The aim of this clinical trial was to evaluate the effects of sitagliptin on the metabolic profile and liver test results in metformin-treated patients with T2DM and NAFLD.</div></div><div><h3>Methods</h3><div>This was a prospective, 12-week, single-center, comparative randomized clinical trial enrolling 66 adult patients with T2DM and NAFLD (diagnosed by ultrasound). Patients were randomly assigned to either metformin (2000 mg/d, n = 33) or sitagliptin + metformin (100 and 2000 mg/d, respectively, n = 33), administered orally. Certain metabolic parameters, that is, fasting blood sugar (FBS), glycosylated hemoglobin, triglycerides (TGs), total cholesterol (TC), low-density lipoprotein cholesterol, vitamin D3 (vitD3), alkaline phosphatase, alanine aminotransferase (SGPT), and aspartate aminotransferase, were measured at baseline and after 12 weeks. Triglyceride-glucose (TG-G) index was also calculated.</div></div><div><h3>Results</h3><div>All biochemical variables decreased by a greater extent in the sitagliptin + metformin group than in the metformin group, with differences in FBS (<em>P</em> = 0.030), TC (<em>P</em> = 0.017), TG (<em>P</em> = 0.008), SGPT (<em>P</em> = 0.018), and vitD3 (<em>P</em> = 0.001) reaching statistical significance. Furthermore, the mean reduction of the TG-G index was significantly greater in the sitagliptin + metformin group than in the metformin group (0.67 vs 0.21, respectively; <em>P</em> = 0.017).</div></div><div><h3>Conclusions</h3><div>Sitagliptin + metformin therapy led to significantly greater improvements in FBS, TC, TG, SGPT, vitD3, and TG-G compared with the metformin monotherapy group. Other biomarkers also decreased more in the sitagliptin + metformin group than in the metformin group, but these differences did not reach statistical significance. The present findings should be interpreted with caution, although they suggest certain metabolic benefits after sitagliptin addition in metformin-treated patients with T2DM and NAFLD. Further studies are required to elucidate these effects and provide strong evidence for safe conclusions.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"101 ","pages":"Article 100764"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142661007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers of Hepatic Toxicity: An Overview","authors":"Simran Thakur Pharm.D ,&nbsp;Vishal Kumar Pharm.D ,&nbsp;Rina Das PhD ,&nbsp;Vishal Sharma M.Pharm ,&nbsp;Dinesh Kumar Mehta PhD","doi":"10.1016/j.curtheres.2024.100737","DOIUrl":"https://doi.org/10.1016/j.curtheres.2024.100737","url":null,"abstract":"<div><h3>Background</h3><p>Hepatotoxicity is the foremost issue for clinicians and the primary reason for pharmaceutical product recalls. A biomarker is a measurable and quantifiable attribute used to evaluate the efficacy of a treatment or to diagnose a disease. There are various biomarkers which are used for the detection of liver disease and the intent of liver damage.</p></div><div><h3>Objective</h3><p>This review aims to investigate the current state of hepatotoxicity biomarkers and their utility in clinical settings. Using hepatic biomarkers, the presence of liver injury, its severity, prognosis, causative agent, and type of hepatotoxicity can all be determined.</p></div><div><h3>Methods</h3><p>Relevant published articles up to 2022 were systematically retrieved from MEDLINE/PubMed, SCOPUS, EMBASE, and WOS databases using keywords such as <em>drug toxicity, hepatotoxicity biomarkers, biochemical parameters,</em> and <em>nonalcoholic fatty liver disease.</em></p></div><div><h3>Results</h3><p>In clinical trials and everyday practice, biomarkers of drug-induced liver injury are essential for spotting the most severe cases of hepatotoxicity. Hence, developing novel biomarker approaches to enhance hepatotoxicity diagnosis will increase specificity and/or identify the person at risk. Importantly, early clinical studies on patients with liver illness have proved that some biomarkers such as aminotransferase, bilirubin, albumin, and bile acids are even therapeutically beneficial.</p></div><div><h3>Conclusions</h3><p>By assessing the unique signs of liver injury, health care professionals can rapidly and accurately detect liver damage and evaluate its severity. These measures contribute to ensuring prompt and effective medical intervention, hence reducing the risk of long-term liver damage and other major health concerns.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100737"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000079/pdfft?md5=6f1feaca117e461ea1d3ae6f40f48626&pid=1-s2.0-S0011393X24000079-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141078694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-leukemia effects of ginsenoside monomer: A narrative review of pharmacodynamics study","authors":"Seyyed Mohammad Matin Alavi Dana ,&nbsp;Mohammadreza Meghdadi ,&nbsp;Saeed Khayat Kakhki ,&nbsp;Reza Khademi","doi":"10.1016/j.curtheres.2024.100739","DOIUrl":"10.1016/j.curtheres.2024.100739","url":null,"abstract":"<div><h3>Background</h3><p>Leukemia is a prevalent disease with high mortality and morbidity rates. Current therapeutic approaches are expensive and have side effects.</p></div><div><h3>Objective</h3><p>In this investigation, we reviewed studies that investigated the anticancer effects of ginsenoside derivatives against leukemia and also explained the three main Ginsenoside derivatives (ginsenoside Rg3, Rh2, and Rg1) separately.</p></div><div><h3>Methods</h3><p>An extensive search was conducted in Pubmed, Web of Science, and Google Scholar and relevant studies that investigated anticancer effects of ginsenoside derivatives against leukemia cancer were extracted and reviewed.</p></div><div><h3>Results</h3><p>Preclinical studies reported that ginsenoside derivatives can induce apoptosis, suppress the proliferation of cancer cells, and induce differentiation and cell cycle arrest in leukemia cells. in addition, it can suppress the chemokine activity and extramedullary infiltration of leukemia cells from bone marrow. using herbal medicine and its derivatives is a promising approach to current health problems.</p></div><div><h3>Conclusion</h3><p>This review shows that ginsenoside derivatives can potentially suppress the growth of leukemia cells via various pathways and can be applied as a new natural medicine for future clinical research.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100739"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000092/pdfft?md5=698bcf91b99aae7f70c8b2cf7acb6237&pid=1-s2.0-S0011393X24000092-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140469300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microbiological and Molecular Study of Paranasal Sinus Infections of Children with Malignancy and Unknown Origin Fever in Markazi Province, Iran","authors":"Kazem Ghaffari ,&nbsp;Vahid Falahati ,&nbsp;Tahereh Motallebirad ,&nbsp;Mahdi Safarabadi ,&nbsp;Amir Hossein Tashakor ,&nbsp;Davood Azadi","doi":"10.1016/j.curtheres.2024.100745","DOIUrl":"10.1016/j.curtheres.2024.100745","url":null,"abstract":"<div><h3>Background</h3><p>Children with malignancies are vulnerable to various infections, including sinus infections. Sinusitis is primarily caused by bacterial infections, followed by fungal infections. Due to this, evaluating the occurrence, diversity, and antibiotic susceptibility patterns of bacterial species that cause paranasal sinus infections in children with malignancy and unexplained fever is important.</p></div><div><h3>Objective</h3><p>To investigate the bacterial species accountable for sinusitis in children with malignancy and unexplained fever, and determine their susceptibility to antibiotics.</p></div><div><h3>Methods</h3><p>The study involved collecting 90 sinus samples from children aged 5 to 15 years with malignancy in Arak City, Iran. The isolates were identified using a combination of phenotypic, biochemical, and molecular techniques, including specific polymerase chain reaction and 16S ribosomal RNA gene sequencing. Drug susceptibility testing was performed following the Clinical &amp; Laboratory Standards Institute 2021 guidelines.</p></div><div><h3>Results</h3><p>A total of 36 isolates (40%) were obtained, including 4 isolates of <em>Nocardia</em> (11.12%), 4 isolates of <em>Escherichia coli</em> (11.12%), 3 isolates of <em>Klebsiella pneumoniae</em> (8.33%), 5 isolates of <em>Pseudomonas aeruginosa</em> (13.88%), 3 isolates of <em>Acinetobacter baumannii</em> (8.33%), 4 isolates of <em>Staphylococcus aureus</em> (11.12%), 3 isolates of <em>Staphylococcus epidermidis</em> (8.33%), 5 isolates of <em>Streptococcus agalactiae</em> (13.88%), 2 isolates of <em>Streptococcus pneumoniae</em> (5.55%), and 3 isolates <em>of Enterococcus faecium</em> (8.33%). The isolates showed the most sensitivity to imipenem and trimethoprim-sulfamethoxazole and the least sensitivity to erythromycin and tetracycline.</p></div><div><h3>Conclusions</h3><p>The findings of the study indicate that sinusitis can contribute to fever of unknown origin in patients with cancer. Therefore, it is recommended to use a combination of molecular and phenotypic methods for accurate identification of isolates. This approach can provide more reliable and precise results, leading to better diagnosis and treatment of sinusitis infections in children with malignancy.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100745"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000158/pdfft?md5=eccc4a27000e7a689b24cad5857bc806&pid=1-s2.0-S0011393X24000158-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140270240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}